4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-21-004452
General Counsel and Secretary sold 27,500 shares at an average $204.94 ($5,635,944)
- General Counsel and Secretary acquired 27,500 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| KASINGER JAMES R. General Counsel and Secretary | 2021-01-19 | Option exercise | +27,500 | $51.49 | $1,415,975 | 49,931 | D |
| KASINGER JAMES R. General Counsel and Secretary | 2021-01-19 | Sale | −6,785 | $203.58 | $1,381,290 | 43,146 | D |
| KASINGER JAMES R. General Counsel and Secretary | 2021-01-19 | Sale | −7,818 | $204.40 | $1,597,999 | 35,328 | D |
| KASINGER JAMES R. General Counsel and Secretary | 2021-01-19 | Sale | −8,997 | $205.60 | $1,849,783 | 26,331 | D |
| KASINGER JAMES R. General Counsel and Secretary | 2021-01-19 | Sale | −1,800 | $206.05 | $370,890 | 24,531 | D |
| KASINGER JAMES R. General Counsel and Secretary | 2021-01-19 | Sale | −2,100 | $207.61 | $435,981 | 22,431 | D |
| Derivatives | |||||||
| KASINGER JAMES R. General Counsel and Secretary | 2021-01-19 | Option exercise · Stock Option (right to buy) | −27,500 | 12,500 | D | ||
| Open-market sales · 27,500 sh · avg $204.94 · $5,635,944 | |||||||
Loading xslF345X03/doc4.xml…